MX2020013570A - Compuestos de purinona y su uso en el tratamiento del cancer. - Google Patents
Compuestos de purinona y su uso en el tratamiento del cancer.Info
- Publication number
- MX2020013570A MX2020013570A MX2020013570A MX2020013570A MX2020013570A MX 2020013570 A MX2020013570 A MX 2020013570A MX 2020013570 A MX2020013570 A MX 2020013570A MX 2020013570 A MX2020013570 A MX 2020013570A MX 2020013570 A MX2020013570 A MX 2020013570A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- sup
- salts
- treating cancer
- manufacture
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- UFZNZKGKBWOSJG-UHFFFAOYSA-N purin-2-one Chemical class O=C1N=CC2=NC=NC2=N1 UFZNZKGKBWOSJG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 7
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Measurement Of Radiation (AREA)
Abstract
La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (ver Fórmulas) y sales farmacéuticamente aceptables de los mismos, donde R1, A1, A2 y A3 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir una enfermedad mediada por PC-ADN, incluyendo el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales; kits que comprenden tales compuestos y sales; métodos de fabricación de dichos compuestos y sales; intermedios útiles en la fabricación de dichos compuestos y sales; y a los métodos para tratar una enfermedad mediada por PC-ADN, incluyendo el cáncer, usando dichos compuestos y sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685325P | 2018-06-15 | 2018-06-15 | |
| PCT/EP2019/065686 WO2019238929A1 (en) | 2018-06-15 | 2019-06-14 | Purinone compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013570A true MX2020013570A (es) | 2021-05-27 |
Family
ID=67107385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013570A MX2020013570A (es) | 2018-06-15 | 2019-06-14 | Compuestos de purinona y su uso en el tratamiento del cancer. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11884671B2 (es) |
| EP (1) | EP3807278B1 (es) |
| JP (1) | JP7472044B2 (es) |
| KR (1) | KR102793666B1 (es) |
| CN (1) | CN112236431B (es) |
| AR (1) | AR114971A1 (es) |
| AU (1) | AU2019287295B2 (es) |
| BR (1) | BR112020025127A2 (es) |
| CA (1) | CA3102195A1 (es) |
| CL (1) | CL2020003131A1 (es) |
| CO (1) | CO2020015758A2 (es) |
| CR (1) | CR20200620A (es) |
| DO (1) | DOP2020000241A (es) |
| EA (1) | EA202190006A1 (es) |
| EC (1) | ECSP20080276A (es) |
| ES (1) | ES2931448T3 (es) |
| IL (1) | IL279370B2 (es) |
| JO (1) | JOP20200315A1 (es) |
| MA (1) | MA52886A (es) |
| MX (1) | MX2020013570A (es) |
| NI (1) | NI202000099A (es) |
| PE (1) | PE20210003A1 (es) |
| PH (1) | PH12020552148A1 (es) |
| SG (1) | SG11202012035WA (es) |
| TW (1) | TWI820146B (es) |
| UA (1) | UA126837C2 (es) |
| UY (1) | UY38263A (es) |
| WO (1) | WO2019238929A1 (es) |
| ZA (1) | ZA202100195B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| IL293318A (en) * | 2019-11-25 | 2022-07-01 | Medshine Discovery Inc | Pyrimidoimidazole compounds used as dna-pk inhibitors |
| JP7428806B2 (ja) * | 2019-12-31 | 2024-02-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
| CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| WO2021136462A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| WO2021204111A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物 |
| MX2022013054A (es) * | 2020-04-17 | 2022-11-09 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivados de imidazolidinona y uso medico de los mismos. |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| CN116406272A (zh) * | 2020-07-20 | 2023-07-07 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| AU2021346954A1 (en) * | 2020-09-24 | 2023-05-25 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| CN116685323A (zh) * | 2020-12-21 | 2023-09-01 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| CN114656486B (zh) * | 2020-12-22 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
| WO2022199547A1 (zh) * | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| WO2023274310A1 (zh) * | 2021-06-29 | 2023-01-05 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| WO2023036156A1 (zh) * | 2021-09-07 | 2023-03-16 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| WO2025199376A1 (en) * | 2024-03-22 | 2025-09-25 | Padarn Therapeutics, Inc. | Cdk2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2212326A1 (en) * | 2007-08-23 | 2010-08-04 | AstraZeneca AB | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| EP2417138B1 (en) * | 2009-04-09 | 2019-11-27 | Merck Sharp & Dohme Corp. | Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors |
| PL2493895T3 (pl) * | 2009-10-29 | 2017-10-31 | Vectura Ltd | Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3 |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| PH12013501855A1 (en) * | 2011-03-11 | 2018-03-21 | Gilead Calistoga Llc | Combination therapies for hematologic malignancies |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| KR102220971B1 (ko) * | 2016-12-20 | 2021-02-25 | 아스트라제네카 아베 | 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도 |
-
2019
- 2019-06-06 TW TW108119642A patent/TWI820146B/zh active
- 2019-06-14 ES ES19734289T patent/ES2931448T3/es active Active
- 2019-06-14 BR BR112020025127-5A patent/BR112020025127A2/pt unknown
- 2019-06-14 SG SG11202012035WA patent/SG11202012035WA/en unknown
- 2019-06-14 PE PE2020002005A patent/PE20210003A1/es unknown
- 2019-06-14 CN CN201980038412.5A patent/CN112236431B/zh active Active
- 2019-06-14 EP EP19734289.2A patent/EP3807278B1/en active Active
- 2019-06-14 KR KR1020207037917A patent/KR102793666B1/ko active Active
- 2019-06-14 IL IL279370A patent/IL279370B2/en unknown
- 2019-06-14 AR ARP190101659A patent/AR114971A1/es unknown
- 2019-06-14 CA CA3102195A patent/CA3102195A1/en active Pending
- 2019-06-14 UA UAA202100011A patent/UA126837C2/uk unknown
- 2019-06-14 JO JOP/2020/0315A patent/JOP20200315A1/ar unknown
- 2019-06-14 MX MX2020013570A patent/MX2020013570A/es unknown
- 2019-06-14 UY UY0001038263A patent/UY38263A/es active IP Right Grant
- 2019-06-14 US US16/973,862 patent/US11884671B2/en active Active
- 2019-06-14 WO PCT/EP2019/065686 patent/WO2019238929A1/en not_active Ceased
- 2019-06-14 MA MA052886A patent/MA52886A/fr unknown
- 2019-06-14 CR CR20200620A patent/CR20200620A/es unknown
- 2019-06-14 AU AU2019287295A patent/AU2019287295B2/en active Active
- 2019-06-14 EA EA202190006A patent/EA202190006A1/ru unknown
- 2019-06-14 JP JP2020569143A patent/JP7472044B2/ja active Active
-
2020
- 2020-12-02 CL CL2020003131A patent/CL2020003131A1/es unknown
- 2020-12-09 DO DO2020000241A patent/DOP2020000241A/es unknown
- 2020-12-10 NI NI202000099A patent/NI202000099A/es unknown
- 2020-12-11 EC ECSENADI202080276A patent/ECSP20080276A/es unknown
- 2020-12-12 PH PH12020552148A patent/PH12020552148A1/en unknown
- 2020-12-15 CO CONC2020/0015758A patent/CO2020015758A2/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00195A patent/ZA202100195B/en unknown
-
2023
- 2023-12-14 US US18/540,129 patent/US20240150355A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013570A (es) | Compuestos de purinona y su uso en el tratamiento del cancer. | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| TN2016000458A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer. | |
| PH12020551572A1 (en) | Heterocyclic compounds as immunomodulators | |
| AU2019231551A8 (en) | Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones | |
| ZA202006137B (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MY192861A (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX384930B (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer. | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| MX2018011283A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. |